---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-029090"
form_type: "8-K"
ticker: null
cik: "0000827871"
company_name: "EAGLE PHARMACEUTICALS, INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:37:25.376561+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eagle Pharmaceuticals cuts workforce 36% in realignment plan; expects $3.5M cash charges

## Summary
- Board approved Realignment Plan reducing workforce ~36%, affecting employees supporting Byfavo, Barhemsys, Ryanodex.
- Estimated $3.5M cash charges: $3.1M severance/healthcare, $0.4M retention benefits; recorded in Q1 2024.
- Plan substantially complete by end of Q1 2024; company to continue commercialization with reduced team plus oncology sales.
- Also performing impairment analysis over certain long-lived assets and inventory; may record non-cash impairment charges.

## SEC filing metadata
- accession: 0001104659-24-029090
- form_type: 8-K
- cik: 0000827871
- company_name: EAGLE PHARMACEUTICALS, INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/0001104659-24-029090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/tm247572d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-029090
- JSON: https://secwatch.observer/filing/0001104659-24-029090.json
- Plain text: https://secwatch.observer/filing/0001104659-24-029090.txt

## Key facts
- Restructurings & Charges
  EAGLE PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.5 million in cash charges affecting commercialization of Byfavo, Barhemsys and Ryanodex (approximately 36%).
  - Type: restructuring
  - Charge: approximately $3.5 million in cash charges
  - Affected area: commercialization of Byfavo, Barhemsys and Ryanodex
  - Headcount: approximately 36%
  source text: expenditures relating to the Realignment Plan will not be known until all related activities have been completed. The Company estimates that it will incur approximately $3.5 million in cash charges in connection with the Realignment Plan, consisting of (i) approximately $3.1 million in cash-based expenses related to employee severance payments and healthcare
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/0001104659-24-029090-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.